Cargando…

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection

The incidence of heart failure and chronic kidney disease is increasing, and many patients develop both diseases. Angiotensin receptor‐neprilysin inhibitor (ARNI) is a promising therapeutic candidate for both diseases. ARNI has demonstrated superior cardioprotective effects compared with renin–angio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukamoto, Shunichiro, Uehara, Tatsuki, Azushima, Kengo, Wakui, Hiromichi, Tamura, Kouichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Contemporary Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227251/ https://www.ncbi.nlm.nih.gov/pubmed/37066800 http://dx.doi.org/10.1161/JAHA.122.029565

Ejemplares similares

Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome
por: Tsukamoto, Shunichiro, et al.
Publicado: (2023)

Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization
por: Abe, Eriko, et al.
Publicado: (2022)

Author Correction: Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization
por: Abe, Eriko, et al.
Publicado: (2022)

Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Tsukamoto, Shunichiro, et al.
Publicado: (2022)

Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease
por: Ohsawa, Masato, et al.
Publicado: (2013)

Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease
por: Tsukamoto, Shunichiro, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension
por: Azushima, Kengo, et al.
Publicado: (2022)

Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy
por: Taguchi, Shinya, et al.
Publicado: (2021)

Angiotensin II Type 1 Receptor‐Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin
por: Uneda, Kazushi, et al.
Publicado: (2017)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Effects of a High-Protein Diet on Kidney Injury under Conditions of Non-CKD or CKD in Mice
por: Tanaka, Shohei, et al.
Publicado: (2023)

L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
por: Kanaoka, Tomohiko, et al.
Publicado: (2013)

Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
por: Ohsawa, Masato, et al.
Publicado: (2015)

Effects of Single Pill-Based Combination Therapy of Amlodipine and Atorvastatin on Within-Visit Blood Pressure Variability and Parameters of Renal and Vascular Function in Hypertensive Patients with Chronic Kidney Disease
por: Azushima, Kengo, et al.
Publicado: (2014)

Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice
por: Azushima, Kengo, et al.
Publicado: (2019)

Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice
por: Urate, Shingo, et al.
Publicado: (2021)

Effects of the Angiotensin Receptor Blocker Olmesartan on Adipocyte Hypertrophy and Function in Mice with Metabolic Disorders
por: Maeda, Akinobu, et al.
Publicado: (2014)

Upstream Stimulatory Factors 1 and 2 Mediate the Transcription of Angiotensin II Binding and Inhibitory Protein
por: Matsuda, Miyuki, et al.
Publicado: (2013)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Angiotensin Receptor–Binding Protein ATRAP/Agtrap Inhibits Metabolic Dysfunction With Visceral Obesity
por: Maeda, Akinobu, et al.
Publicado: (2013)

The pathophysiological role of angiotensin receptor-binding protein in hypertension and kidney diseases: Oshima Award Address 2019
por: Wakui, Hiromichi
Publicado: (2020)

Adipocyte‐Specific Enhancement of Angiotensin II Type 1 Receptor‐Associated Protein Ameliorates Diet‐Induced Visceral Obesity and Insulin Resistance
por: Azushima, Kengo, et al.
Publicado: (2017)

Inequity in Cardio‐Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes
por: Ohman, Rachel E., et al.
Publicado: (2021)

Effects of ATRAP in Renal Proximal Tubules on Angiotensin‐Dependent Hypertension
por: Kinguchi, Sho, et al.
Publicado: (2019)

Enhancement of intrarenal plasma membrane calcium pump isoform 1 expression in chronic angiotensin II‐infused mice
por: Wakui, Hiromichi, et al.
Publicado: (2017)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
por: Uneda, Kazushi, et al.
Publicado: (2021)

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease
por: Kinguchi, Sho, et al.
Publicado: (2021)

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney
por: Domenig, Oliver, et al.
Publicado: (2016)

Deletion of the angiotensin II type 1 receptor–associated protein enhances renal sodium reabsorption and exacerbates angiotensin II–mediated hypertension
por: Ohsawa, Masato, et al.
Publicado: (2014)

Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
por: Gronda, Edoardo, et al.
Publicado: (2020)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
por: Gan, Liangying, et al.
Publicado: (2022)

Blood Pressure Elevation of Tubular Specific (P)RR Transgenic Mice and Lethal Tubular Degeneration due to Possible Intracellular Interactions between (P)RR and Alternative Renin Products
por: Saigo, Sae, et al.
Publicado: (2021)

Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease
por: Hung, Szu‐Chun, et al.
Publicado: (2017)

Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue
por: Ohki, Kohji, et al.
Publicado: (2018)

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan
por: Kanai, Daisuke, et al.
Publicado: (2022)

Native T1 time and extracellular volume fraction in differentiation of normal myocardium from non-ischemic dilated and hypertrophic cardiomyopathy myocardium: A systematic review and meta-analysis
por: Minegishi, Shintaro, et al.
Publicado: (2019)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
por: Yamada, Takayuki, et al.
Publicado: (2021)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Role of ACE, ACE2 and Neprilysin in the Kidney
por: Chappell, Mark C.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_11bvcom94cd2qderls39lbushv